Market revenue in 2023 | USD 895.7 million |
Market revenue in 2030 | USD 1,523.1 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Molecular diagnostics |
Fastest growing segment | Immunoassays |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoassays, Hematology and Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy |
Key market players worldwide | Quest Diagnostics Inc, 23andMe Holding Co Class A, Abbott Laboratories, Guardant Health Inc, NeoGenomics, Siemens Healthineers AG ADR, Qiagen NV, Illumina Inc, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to laboratory developed tests market will help companies and investors design strategic landscapes.
Molecular diagnostics was the largest segment with a revenue share of 26.73% in 2023. Horizon Databook has segmented the Germany laboratory developed tests market based on immunoassays, hematology and coagulation, molecular diagnostics, microbiology, clinical chemistry, histology/cytology, flow cytometry, mass spectroscopy covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has a well-established healthcare system and medical innovation industry owing to increasing demand for LDTs in the country. Several companies in Germany, such as Roche Diagnostics, QIAGEN, bioMérieux, Siemens Healthineers, and Agilent Technologies, are involved in the development of LDTs, which focus on the development of innovative solutions for the healthcare industry.
Several initiatives by companies in the field of LDTs have contributed to the country’s market growth. For instance, in October 2022, QIAGEN announced receiving CE-mark approval for its automated testing platform NeuMoDx, and for in-vitro diagnostic kit under new EU IVDR regulation.
The healthcare system in the country focuses on the use of innovative technologies to improve patient outcomes, owing to which there is a growing demand for high-quality LDTs in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany laboratory developed tests market , including forecasts for subscribers. This country databook contains high-level insights into Germany laboratory developed tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account